Regeneron and Sanofi's fast track-designated REGN2810, or cemiplimab, for adult patients with metastatic and locally and unresectable advanced cutaneous squamous cell carcinoma was granted breakthrough therapy designation by the FDA. An early-stage trial demonstrated a 46% overall response rate and a 69% disease control rate with the drug.
Regeneron, Sanofi's skin cancer drug gains breakthrough therapy status
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.